We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Feb 4, 2019

12th International Conference on Advanced Technologies & Treatments for Diabetes

A RETROSPECTIVE CASE STUDY OF 12 WEEKS TO ASSESS GLYCEMIC AND NON-GLYCEMIC CHANGES WITH SGLT2I FROM DATA BASE OF 6 TYPE 2 DIABETIC PATIENTS

sodium glucose cotransporter 2 inhibitor

packed cell volume change

type 2 diabetes

waist circumference change

homa ir change

Abstract

14

Views

14

Views

Abstract

Fullscreen

thumbnail

Keywords

sodium glucose cotransporter 2 inhibitor

packed cell volume change

type 2 diabetes

waist circumference change

homa ir change

Abstract

Introduction: Sodium-glucose transporter-2 (SGLT-2) inhibitors are newer agents with the advantage of weight loss. We have used SGLT-2 inhibitors –dapagliflozin, or, empagliflozin on T2D patients inadequately controlled on existing therapy and analyzed the results on glycemic and other non-glycemic parameters. Methods: We have clinic data of 6 patients collected after taking their written consent. Patients received treatment with SGLT2Is as per routine standard of care. The patients’ physical parameters (weight, waist circumference), C-reactive protein (CRP), packed cell volume (PCV), Hemoglobin (Hb), HOMA-Insulin resistance (HOMA IR) and HbA1c were taken from baseline clinic's data and their clinic data after 12 weeks of treatment. Results: After a mean study duration of 12 weeks, there was significant reduction in weight from 73 ± 2.48 kg (mean ± SEM) to 67.83 ± 2.32 kg ( reduction of 5.17 ± 2.14;p=0.003) along with significant increase in the packed cell volume (PCV) from 36.17 ± 2.05 (mean ± SEM) to 39.07 ± 1.81 (increase of 2.90 ± 2.07%; p=0.027). The waist circumference also reduced from 106.96 ± 7.96 to 102.33 ± 5.98. The hemoglobin also increased significantly from 11.85 ± 0.6 to 12.77 ± 0.681. Other parameters such as waist circumference, CRP, HOMA-IR, HbA1c remained unchanged (Table 1). Conclusion: There seems to be a persistence of non-glycemic index changes even without the change in HbA1c with the use of SGLT2Is. The changes in PCV and Hemoglobin throw a faint light on the chance of change of erythropoietin level with SGLT2I use in diabetics (as seen in other studies).

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.